The Effects of Mindfulness-based Stress Reduction in Interstitial Cystitis Patients

July 21, 2020 updated by: TriHealth Inc.

The Effects of Mindfulness-based Stress Reduction on the Urinary Microbiome in Patients With Interstitial Cystitis/Painful Bladder Syndrome

This is a prospective cohort study to investigate differences in the bladder environment (i.e. urinary microbiome) amongst women with interstitial cystitis (IC) before and after undergoing mindfulness-based stress reduction (MBSR) treatment, including yoga and meditation practices.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Interstitial cystitis (IC), or Painful Bladder Syndrome (PBS) is a debilitating condition of the bladder that is estimated to affect 3-8 million women in the United States. The pathophysiology of the disease is poorly understood, and thus treatment modalities and treatment efficacy vary widely. Lately, much attention has shifted toward investigating how the bladder 'environment' differs amongst women with IC compared to those who do not suffer from IC.

Mindfulness-based stress reduction (MBSR), a complementary alternative medicine (CAM)-based therapy, is a standardized program including components of meditation and yoga. Recent studies show that MBSR improves symptoms in the IC patient population.

The purpose of this study is to compare measurable differences in the urinary microbiome among women with IC before and after MBSR treatment.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Cincinnati, Ohio, United States, 45220
        • TriHealth - Cincinnati Urogynecology Associates

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Adults 18 years of age or older
  • English-speaking
  • Established patient of Cincinnati Urogynecology Associates, TriHealth Inc.
  • Current diagnosis of IC/PBS, as defined by the American Urological Association (AUA)
  • Negative urinalysis or urine culture within 2 months of enrollment
  • Currently undergoing first or second-line treatment for IC, as defined by the AUA
  • Willingness to participate in study

Exclusion Criteria:

  • Non-English speaking
  • Unwillingness to participate in study
  • Pregnancy or breastfeeding
  • Physical or mental impairment that would affect the subject's ability to participate in the MBSR treatment, including patients with Dementia, Parkinsonism, or those who have impaired mobility or hearing
  • Current or expected prolonged catheterization
  • Expected travel or surgery that would hinder the ability to attend all eight MBSR sessions
  • Undergoing third-, fourth-, fifth-, or sixth-line treatment for IC as defined by the AUA
  • Subjects on antibiotics currently or prior use within one week of consenting

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Mindfulness Cohort
Mindfulness-based stress reduction (MBSR) treatment group
Guided yoga and meditation practices

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in the urinary microbiome before and after MBSR treatment
Time Frame: Before intervention and after completion of the intervention, up to 9 weeks
Urinary microbiome sequencing analysis will be performed by Resphera Biosciences Laboratory
Before intervention and after completion of the intervention, up to 9 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 7, 2019

Primary Completion (Actual)

January 15, 2020

Study Completion (Actual)

March 15, 2020

Study Registration Dates

First Submitted

October 24, 2018

First Submitted That Met QC Criteria

October 25, 2018

First Posted (Actual)

October 29, 2018

Study Record Updates

Last Update Posted (Actual)

July 23, 2020

Last Update Submitted That Met QC Criteria

July 21, 2020

Last Verified

November 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 18-056

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Interstitial Cystitis

Clinical Trials on MBSR

3
Subscribe